It was in Glassman's own divorce case, though, that the CrossFit defense arsenal launched its full firepower. Lauren and Greg's marriage hit the rocks in 2009. Lauren became pregnant with twins and could no longer travel to the seminars.Greg, wrapped up with CrossFit, became more and more distant. Rumors of infidelity swirled. Soon the two were living in separate houses. In March 2010, Lauren officially filed for divorce. But the case didn't come to a head until July 2012, when Lauren filed a motion to sell her 50 percent stake in the company to Anthos Capital, a Menlo Park, California-based venture capital firm, for $20 million. Glassman, and in short order CrossFit, hit the ceiling.
The WHO trial (so named because the international team of principal investigators contained World Health Organization members) tested the potential of clofibrate, a “pre-statin” cholesterol-lowering agent, to reduce heart attack morbidity and mortality. The investigators ultimately concluded that clofibrate "cannot be recommended as a lipid-lowering drug for community-wide primary prevention of ischaemic heart disease.” Nevertheless, clofibrate remained in use until 2002, when it was pulled for increasing cancer rates. In their review of studies such as the WHO trial, Uffe Ravnskov and David Diamond observe, “Despite the largely disappointing findings from 50 years of cholesterol lower[ing] trials, the indictment and conviction of cholesterol as the causal agent in CVD [cardiovascular disease] has stood the test of time. … [Yet] the grand effort to reduce cholesterol as a strategy to improve health has failed.”